Pharmaceuticals, Biotechnology and Life Sciences
Shire will now be able to use its Adynovate for treating heamophilia A in children younger than 12 years of age, as the the U.S. Food and Drug Administration (FDA) has approved it for that age group. The FDA has also…
When her father’s lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly $3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.
A drug distributor owned by Cardinal Health Inc has agreed to pay $10 million to resolve claims that it failed to alert the U.S. Drug Enforcement Administration to suspicious orders of addictive painkillers by New York-area pharmacies.
Israeil’s largest drugmaker Teva Pharmaceuticals Industries has settled with the United States government over international bribery of government officials in…
TiGenix has submitted its responses to the European Medicines Agency`s (EMA) Day 120 List of Questions for Cx601, its lead…
AstraZeneca has sold to Pfizer the commercialization and development rights of its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.
Xbrane Biopharma has named Anders P. Wiklund as strategic advisor. He presently serves on the boards of EffRx Pharmaceuticals SA, Inspirion Delivery Technologies LLC, Life Medical AB and IRRAS AB.
Roche’s phase III study of haemophilia drug emicizumab prophylacis for 12 yearolds and older has met its primary endpoint, as…
Ablynx has received a notification of shareholdings from FMR LLC, according to which its stake in Ablynx has slightly increased.
ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough…